MAPK3 and autosomal dominant polycystic kidney disease: Recently, Nastaran et al. evaluated the efficacy and safety of SS-31 against autosomal dominant polycystic kidney disease during pregnancy using pregnant Pkd1RC/RC mice and found that it downregulated ERK1/2 phosphorylation, improved mitochondrial supercomplex formation, and inhibited the progression of autosomal dominant polycystic kidney disease.